Neuromyelitis Optica (NMO) — Study Review
DOI:
https://doi.org/10.15225/PNN.2021.10.2.6Keywords
aquaporin 4, demyelinating diseases, neuromyelitis optica, nurseAbstract
Neuromyelitis optica (NMO, Devic’s disease) is a rare autoimmune, demyelinating disease of the central nervous system (CNS), mainly affecting the optic nerves and spinal cord. For a very long time it was considered as a variant of multiple sclerosis (MS). In 2004 antibodies against aquaporin 4 (AQP4) were discovered. AQP4 is a water channel which plays a central role in the pathogenesis of NMO. Typical NMO is characterized by optic neuritis (ON) with longitudinal extensive transverse myelitis (LETM). Recommended therapeutic options for acute attacks of NMO include high doses of corticosteroids and/or plasma exchange. In long-term treatment a lot of immuno-suppressants are used. In recent years there has been an increased range of treatment options, which may prevent relapses and allow a better outcome. In NMO, as for MS, the role of the nurse is very important. (JNNN 2021;10(2):82–85)
References
Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
Lennon V.A., Wingerchuk D.M., Kryzer T.J. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112.
Collongues N., Ayme-Dietrich E., Monassier L., de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs. 2019;79(2):125–142.
Damiza-Detmer A., Milewska-Jędrzejczak M., Pawełczyk M., Damiza I., Głąbiński A. Spektrum neuromyelitis optica spectrum disorder (NMOSD) — rozpoznanie, epidemiologia, przebieg kliniczny, leczenie. Aktual Neurol. 2019;19(1):19–26.
Pandit L., Asgari N., Apiwattanakul M. et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015;21(7):845–853.
Jarius S., Wildemann B., Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149–164.
Lotze T.E., Northrop J.L., Hutton G.J., Ross B., Schiffman J.S., Hunter J.V. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122(5):e1039–1047.
Matiello M., Pittock S.J., Porrata L., Weinshenker B.G. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol. 2011;68(7):953–955.
Zéphir H., Fajardy I., Outteryck O. et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler. 2009;15(5):571–579.
Pittock S.J., Lucchinetti C.F. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2016;1366(1):20–39.
Nandhagopal R., Al-Asmi A., Gujjar A.R. Neuromyelitis optica: an overview. Postgrad Med J. 2010;86(1013):153–159.
Mandler R.N. Neuromyelitis optica — Devic’s syndrome, update. Autoimmun Rev. 2006;5(8):537–543.
Kimbrough D.J., Fujihara K., Jacob A. et al. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord. 2012;1(4):180–187.
Traub J., Husseini L., Weber M.S. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals (Basel). 2021;14(1):37.
Selmaj K., Selmaj I. Novel emerging treatments for NMOSD. Neurol Neuroch Pol. 2019;53(5):317–326.
Tradtrantip L., Asavapanumas N., Verkman A.S. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin Ther Targets. 2020;24(3):219–229.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 410
Number of citations: 0